Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Gross Profit (2018 - 2025)

10x Genomics (TXG) has disclosed Gross Profit for 8 consecutive years, with $113.0 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 1.88% to $113.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $443.9 million through Dec 2025, up 7.09% year-over-year, with the annual reading at $443.9 million for FY2025, 7.09% up from the prior year.
  • Gross Profit hit $113.0 million in Q4 2025 for 10x Genomics, up from $100.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $125.1 million in Q2 2025 to a low of $86.9 million in Q2 2022.
  • Historically, Gross Profit has averaged $104.0 million across 5 years, with a median of $102.5 million in 2021.
  • Biggest five-year swings in Gross Profit: surged 237.65% in 2021 and later fell 21.66% in 2022.
  • Year by year, Gross Profit stood at $115.9 million in 2021, then increased by 3.0% to $119.4 million in 2022, then dropped by 3.03% to $115.8 million in 2023, then fell by 4.17% to $111.0 million in 2024, then grew by 1.88% to $113.0 million in 2025.
  • Business Quant data shows Gross Profit for TXG at $113.0 million in Q4 2025, $100.3 million in Q3 2025, and $125.1 million in Q2 2025.